Advertisement

Topics

Companies Related to "Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer" [Most Relevant Company Matches] - Page: 2 RSS

05:57 EDT 21st March 2019 | BioPortfolio

Here are the most relevant search results for "Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer" found in our extensive corporate database of over 50,000 company records.

Showing "Addition Paclitaxel High Dose Combination Chemotherapy Treating Patients" Companies 26–50 of 9,100+

Relevant

Generon (Shanghai) Corporation Ltd.

Generon (Shanghai) Corporation Ltd. is a biotechnology company based in China with a mission to develop innovative biological therapies for patients in China and around the world. F-627 is a newer generation recombinant human granulocyte colony-stimulating factor (G-CSF) that helps the cancer patients to recover from chemotherapy induced neutropenia, a pot...


Bioxel Pharma Inc.

Bioxel is a biopharmaceutical company focused on the manufacture and distribution of taxane pharmaceutical ingredients including paclitaxel, docetaxel, 9-DHB and 10-DAB. The Corporation has rolled out an integrated taxane manufacturing chain that complies with the pharmaceutical industry's highest standards. Drawing on its high-efficiency processes and exclusive technologies, Bioxel guarantees tha...

Targeted Diagnostics and Therapeutics

TDT has emerged as a leader in the development of innovative molecular diagnostics and therapeutics that can improve the quality of life of patients with colorectal cancer and gastrointestinal malignancies. Focused on innovative research and cutting edge technology, TDT has developed highly specific tests to detect colorectal cancer cells in lymph nodes from patients who have undergone surgical st...


Biologics

Biologics is a specialty oncology pharmacy thoughtfully changing the way cancer drugs are dispensed to cancer patients through its Specialty Pharmacy; Clinical Trial Drug Management; Wholesale; Pharmaceutical Product Launch; and Veterinary services. Founded in 1994, Biologics has carved a niche for itself in the $16 billion* specialty pharmacy industry as the first and only specialty pharmacy to d...

BIND Therapeutics and Navidea Biopharmaceuticals

BIND Therapeutics is a clinical-stage nanomedicine platform company developing a pipeline of Accurins™, its novel targeted therapeutics designed to increase the concentration and duration of therapeutic payloads at disease sites while reducing exposure to healthy tissue. BIND is leveraging its Medicinal Nanoengineering® platform to develop a pipeli...

Azaya Therapeutics Inc.

Azaya Therapeutics, Inc. is an oncology company focused on developing more effective cancer treatments through its novel nanotechnology platform. Azaya’s patented Protein Stabilized Liposomes™ (PSL) platform allows for high-dose delivery of potent cytotoxics with potentially lower side effects. ATI-1123, is a novel liposomal encapsulation of Doce...

Delcath Systems, Inc.

Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of pri...

GammaCan

GammaCan is a biopharmaceutical company focused on clinical-phase development and commercialization. GammaCan’s initial therapy under development is a first-in-class anti-cancer immunotherapy aimed at preventing metastasis (the spread of cancer to other parts of the body) of a variety of cancers. GammaCan’s first product was entered to phase-II clinical trials.GammaCan’s innovative treatment...

Protalex, Inc.

Protalex, Inc. is a clinical stage biopharmaceutical company that is developing a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including but not limited to, rheumatoid arthritis. Protalex’s lead product PRTX-100, which is formulated with a highly-purified form of staphylococcal protein A, has completed a Phase 1b...

ViGor Biotics Inc.

Plant made pharmaceutical manufacturer and distributor of generic bulk API Paclitaxel

Lake Champlain Gynecologic Oncology , P.C.

Lake Champlain Gynecologic Oncology is a comprehensive gynecologic oncology center dedicated to the care of women with or suspected of having gynecologic cancers as well as regular gynecologic care for cancer survivors and healthy women. Our office comprises 5500 square feet of easily accessible space with ample on-site parking, 6 exam rooms, a laboratory, a pharmacy, and a chemotherapy infusion c...

Replicon Technologies Incorporated

Replicon Technologies, Inc. (RTI) is an emerging biotechnology company focused on the use of replicons, non-replicating RNA viral particles, for the treatment of patients with cancer. RTI is founded on research and development performed at the University of Alabama at Birmingham (UAB), and supported by competitive grants from the National Institutes of Health, the Department of Defense, and SBIR ...

Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is a specialty pharmaceutical company whose mission is to greatly extend the lives of patients with solid tumor cancers. Intensity Therapeutics is pioneering a new approach to treat cancer referred to as in situ chemovaccination. The Company creates novel, proprietary formulations of proven chemotherapy drugs. These products, w...

Medinox, Inc.

Medinox is a leader in anti-nitric oxide therapeutics and is developing a broad technology platform to address several unmet medical needs including hemodialysis, cardiopulmonary bypass surgery and septic shock. In addition to its nitric oxide technology, Medinox is also developing new and safer NSAID prodrugs for treating arthritic patients. For information about Medinox and its products, please ...

Targeted Diagnostics & Therapeutics, Inc

TDT has emerged as a leader in the development of innovative molecular diagnostics and therapeutics that can improve the quality of life of patients with colorectal cancer and gastrointestinal malignancies. Focused on innovative research and cutting edge technology, TDT has developed highly specific tests to detect colorectal cancer cells in lymph nodes from patients who have undergone surgical st...

Inotek Pharmaceuticals Corp.

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The Company’s lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic developed in Inotek’s laboratories designed to restore the eye’s ...

Bespak Europe

Bespak, founded more than 40 years ago, has established a reputation as a leading supplier of drug delivery technologies and services to the pharmaceutical and biotechnology industries.The company’s comprehensive capabilities have enabled it to develop proprietary drug delivery devices and technologies, many protected by worldwide patents. These include pressurised metered dose inhalers and actu...

Embera NeuroTherapeutics, Inc.

Embera NeuroTherapeutics, Inc. is a development stage pharmaceutical company focused on treating a broad range of addictions and obesity where the major clinical challenge is a limited range of effective drug therapies. Embera is developing a novel drug combination (EMB-001) targeting specific brain functions that drive craving and relapse associated with ...

CerebralRx

Based in Yehud, Israel, CerebralRx was founded in 2010 as a spin-off of BioControl Medical to develop breakthrough implantable neuromodulation systems for the treatment of autonomic nervous system-related neurological disorders. The company’s flagship product is the FitNeS system, an implantable vagus nerve stimulation device for treating patients wit...

Zyga Technology, Inc.

Based in Minneapolis, MN, Zyga Technology, Inc. was founded to develop and market innovative, minimally invasive surgical solutions to treat conditions of the spine. In addition to SImmetry the company is also developing the Glyder(TM) Facet Resurfacing System. Glyder is being developed as a minimally invasive technique for treating patients with facetogenic pain. Zyga has put together a team of ...

NEUPOGEN® (Filgrastim)

NEUPOGEN® (Filgrastim) is Amgen’s first product indicated to decrease the incidence of infection (as manifested by febrile neutropenia)in certain cancer patients who are receiving chemotherapy.

GeNO LLC

GeNO LLC, founded in 2006, is a privately held, advanced development-stage technology company that is developing innovative nitric oxide (NO) generation and delivery platforms to enable the true potential of inhaled nitric oxide to be realized. The company is focused on applying the new technology to deliver inhaled nitric oxide to patients in a wide variety of settings, including ambulatory and ...

Neulasta® (pegfilgrastim)

Neulasta® (pegfilgrastim) is approved for once-per-cycle dosing to decrease the incidence of infection (as manifested by febrile neutropenia)in certain cancer patients who are receiving chemotherapy.

CTCA

CTCA is the home of integrative and compassionate cancer care.We never stop searching for and providing powerful and innovative therapies to heal the whole person, improve quality of life and restore hope. In short, Cancer Treatment Centers of America (CTCA) is committed to helping people overcome cancer. The best way we know how is by listening to our patients. By empowering and encouraging each ...

Parnell Pharmaceuticals

Parnell Pharmaceuticals is the first company dedicated to the research and development of new and innovative products to restore and maintain mucosal integrity, thereby improving the quality of life of those patients, who for diverse reasons are "mucocompromised", and therefore at increased risk for secondary infections. The majority of these patients are defined as immunocompromised for various r...


More From BioPortfolio on "Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks